Comparison of the anti-inflammatoryand therapeutic actions of PPAR-gammaagonists rosiglitazone and troglitazone in experimental colitis

Journal of Physiology and Pharmacology

Volumn 63, Issue 6, 2012, Pages 631-640

  Celinski, K ^a   Dworzanski, T ^a   Fornal, R ^b   Korolczuk, A ^a   Madro, A ^a   Slomka, M ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b John Paul II Public Provincial Hospital   (Poland)

Author keywords

Colitis; Dextran sodium sulphate; Inflammatory bowel diseases; Peroxisome proliferator activated receptors gamma; Rosiglitazone; Troglitazone

Indexed keywords

INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; ROSIGLITAZONE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIINFLAMMATORY AGENT; AUTACOID; CHROMAN DERIVATIVE; DEXTRAN SULFATE; GASTROINTESTINAL AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; ENZYME IMMUNOASSAY; FEMALE; HISTOPATHOLOGY; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; TH1 CELL; TH2 CELL; TISSUE HOMOGENATE; UPREGULATION; ANIMAL; BLOOD; COLON; COMPARATIVE STUDY; DISEASE MODEL; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHROMANS; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL AGENTS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84873421360     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Saraf N, Sharma PK, Mondal SC, Garg VK, Singh AK. Role of PPARγ-2 transcription factor in thiazolidinedione-induced insulin sensitization. J Pharm Pharmacol 2012; 64: 161-171.
2. Xiang GQ, Tang SS, Jiang LY, et al. PPAR-γ agonist pioglitazone improves scopolamine-induced memory impairment in mice. J Pharm Pharmacol 2012; 64: 589-596.
3. Ma JJ, Zhang T, Fang N, et al. Establishment of a cell-based drug screening model for identifying agonists of human peroxisome proliferator-activated receptor gamma (PPAR-γ). J Pharm Pharmacol 2012; 64: 719-726.
4. Celinski K, Dworzanski T, Korolczuk A, et al. Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats. J Physiol Pharmacol 2011; 62: 347-356.
5. Celinski K, Madro A, Prozorow-Krol B, et al. Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ)-specific agonist, as a modulator in experimental acute pancreatitis. Med Sci Monit 2009; 15: 21-29.
6. Celinski K, Dworzanski T, Prozorow-Krol B, Korolczuk A. The role of PPAR-γ receptors in gastrointestinal inflammation diseases. Gastroenterol Pol 2009; 16: 51-56.
7. Andersen V, Christensen J, Ernst A, et al. Polymorphisms in NF-κB, PXR, LXR, PPAR-γ and risk of inflammatory bowel disease. World J Gastroenterol 2011; 17: 197-206.
8. Hontecillas R, Horne WT, Climent M, et al. Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal Immunol 2011; 4: 304-313.
9. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-12956.
10. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferators activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
11. Willson TM, Cobb JE, Cowan DJ, et al. The structure activity relationship between peroxisome proliferatoractivated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-668.
12. Celinski K, Dworzanski T, Prozorow-Krol B, Korolczuk A. Rola receptorow PPAR-γ w przebiegu chorob zapalnych przewodu pokarmowego Gastroenterol Pol 2009; 16: 51-56.
13. Celinski K, Dworzanski T, Korolczuk A, et al. Comparison of main models of experimental colitis essential for studies on novel therapies of inflammatory bowel disease. Gastroenterol Pol 2010; 17: 195-202.
14. Shizuma T, Ishiwata K, Nagano M, Mori H, Fukuyama N. Protective effects of Kurozu and Kurozu Moromimatsu on dextran sulfate sodium-induced experimental colitis. Dig Dis Sci 2011; 56: 1387-1392.
15. Nakashima T, Maeda T, Nagamoto H, Kumakura T, Takai M, Mori T. Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats. Dig Dis Sci 2005; 50(Suppl. 1): S124-S131.
16. Li H, Wu WK, Li ZJ, et al. 2,3',4,4',5'-Pentamethoxy-transstilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice. Br J Pharmacol 2010; 160: 1352-1361.
17. Kumar GK, Dhamotharan R, Kulkarni NM, Honnegowda S, Murugesan S. Embelin ameliorates dextran sodium sulfateinduced colitis in mice. Int Immunopharmacol 2011; 11: 724-731.
18. Cancado GG, Fiuza JA, de Paiva NC, et al. Hookworm products ameliorate dextran sodium sulfate-induced colitis in BALB/c mice. Inflamm Bowel Dis 2011; 17: 2275-2286. doi: 10.1002/ibd.21629.
19. Vasina V, Broccoli M, Ursino MG, et al. Non-peptidyl low molecular weight radical scavenger IAC attenuates DSSinduced colitis in rats. World J Gastroenterol 2010; 16: 3642-3650.
20. Van Dop WA, Marengo S, te Velde AA, et al. The absence of functional PI3Kgamma prevents leukocyte recruitment and ameliorates DSS-induced colitis in mice. Immunol Lett 2010; 131: 33-39.
21. Yamamoto K, Ninomiya Y, Iseki M, et al. 4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor gamma agonist alleviates the symptoms of DSSinduced colitis. Biochem Biophys Res Commun 2008; 367: 566-572.
22. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 2000; 62: 240-248.
23. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69: 238-249.
24. Baginski S. Technika mikroskopowa. PWN, 1969.
25. Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon de la Lastra C. Rosiglitazone, a PPAR-γ ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur J Pharmacol 2007; 562: 247-258.
26. Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon de la Lastra C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 2005; 69: 1733-1744.
27. Takaki K, Mitsuyama K, Tsuruta O, Toyonaga A, Sata M. Attenuation of experimental colonic injury by thiazolidinedione agents. Inflamm Res 2006; 55: 10-15.
28. Tanaka T, Kohno H, Yoshitani S, et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61: 2424-2428.
29. Saubermann LJ, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 2002; 8: 330-339.
30. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001; 193: 827-838.